Dapagliflozin added to rhythm control for early atrial fibrillation
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether a daily medication called dapagliflozin (usually used for diabetes) can improve the success of rhythm control (treatments that bring your heartbeat back to normal) in people with recent atrial fibrillation. If you join, you would receive either the study drug or a placebo along with standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with atrial fibrillation (interrupted or continuous irregular heartbeat) within the last year, confirmed by ECG or Holter monitor.
- You have not previously had any treatment (medication or procedure) to restore normal heart rhythm.
- You have no history of heart failure.
- You have not taken dapagliflozin in the past month.
- You have no other reversible cause of AF, such as overactive thyroid or recent heart surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine called dapagliflozin (usually used for diabetes) can reduce heart tissue changes in people with persistent atrial fibrillation. It is given along with the standard ablation procedure, aiming to improve the heart's electrical health and potentially make the procedure more effective.
This trial tests if the diabetes drug dapagliflozin can lower the chance of atrial fibrillation (an irregular heartbeat) coming back after a procedure called electrical cardioversion, which uses a shock to restore a normal heart rhythm. If you have AF and are scheduled for cardioversion, you may be able to join.
This trial tests if the medicine dapagliflozin (commonly used for diabetes and heart failure) can help prevent atrial fibrillation from coming back after a catheter ablation. By taking this medicine after your first ablation, researchers hope to reduce the chance of the irregular heartbeat returning.
This study tests a new medication, AP31969, to control heart rhythm in people with atrial fibrillation. It compares the drug to a placebo to see if it can reduce how often AF episodes happen over time.
This study tests whether the medication dronedarone can help people with early atrial fibrillation (an irregular heartbeat) get back to a normal rhythm. It may help reduce symptoms and improve long-term heart health.
This trial studies dapagliflozin, a diabetes medicine, to see if it can help people with paroxysmal atrial fibrillation (irregular heart rhythm). If you have both diabetes and this type of AF, the study may offer a chance to improve your heart rhythm and outcomes.
Hear when a new Dapagliflozin (Forxiga) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.